Contents The Eular Journal Editorial 321 Volume 74 Issue 2 | ARD February 2015 381 Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? A-B Aga, E Lie, T Uhlig, I C Olsen, A Wierød, S Kalstad, E Rødevand, K Mikkelsen, T K Kvien, E A Haavardsholm S L Kristensen, I B McInnes, N Sattar Viewpoint 323 Statistical review: frequently given comments Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010 389 OPEN ACCESS S Lydersen Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study Y Tanaka, S Hirata, S Kubo, S Fukuyo, K Hanami, N Sawamukai, K Nakano, S Nakayamada, K Yamaoka, F Sawamura, K Saito Clinical and epidemiological research 326 Editor Associate Editors 333 OPEN ACCESS Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom tothe Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice ofthe Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specifi ed or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on. Copyright: © 2015 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper. Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate K V C Wevers-de Boer, L Heimans, K Visser, J Kälvesten, R J Goekoop, M van Oosterhout, J B Harbers, C Bijkerk, M Steup-Beekman, M P D M de Buck, P B J de Sonnaville, T W J Huizinga, C F Allaart 347 Worsening of pain and function over 5 years in individuals with ‘early’ OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study J Wesseling, S M A Bierma-Zeinstra, M Kloppenburg, R Meijer, J W J Bijlsma 354 OPEN ACCESS Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients M B C´alasan, E den Boer, M C F J de Rotte, S J Vastert, S Kamphuis, R de Jonge, N M Wulffraat Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis M C F J de Rotte, E den Boer, P H P de Jong, S M F Pluijm, M B C´alasan, A E Weel, A M Huisman, A H Gerards, B van Schaeybroeck, N M Wulffraat, J Lindemans, J M W Hazes, R de Jonge 415 OPEN ACCESS Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF␣ inhibitors and rituximab J Listing, J Kekow, B Manger, G-R Burmester, D Pattloch, A Zink, A Strangfeld 422 Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss J-P Pelletier, C Roubille, J-P Raynauld, F Abram, M Dorais, P Delorme, J Martel-Pelletier M Neovius, E V Arkema, H Olsson, J K Eriksson, L E Kristensen, J F Simard, J Askling, for the ARTIS Study Group 361 Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects C L M Krieckaert, S C Nair, M T Nurmohamed, C J J van Dongen, W F Lems, F P J G Lafeber, J W J Bijlsma, H Koffijberg, G Wolbink, P M J Welsing 369 OPEN ACCESS C-F Kuo, M J Grainge, L-C See, K-H Yu, S-F Luo, A M Valdes, W Zhang, M Doherty 375 MORE CONTENTS 䉴 This article has been chosen by the Editor to be of special interest or importance and is freely available online. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins A H Hensvold, P K E Magnusson, V Joshua, M Hansson, L Israelsson, R Ferreira, P-J Jakobsson, R Holmdahl, L Hammarström, V Malmström, J Askling, L Klareskog, A I Catrina Receive regular table of contents by email. Register using this QR code. 402 408 341 Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up E L Kneepkens, J C-C Wei, M T Nurmohamed, K-J Yeo, C Y Chen, I E van der Horst-Bruinsma, D van der Kleij, T Rispens, G Wolbink, C L M Krieckaert E C Keystone, P C Taylor, E Drescher, D E Schlichting, S D Beattie, P-Y Berclaz, C H Lee, R K Fidelus-Gort, M E Luchi, T P Rooney, W L Macias, M C Genovese Editorial office Annals of the Rheumatic Diseases BMJ Publishing Group Ltd BMA House Tavistock Square London WCIH 9JR,UK T: +44 (0)20 7383 6250 F: +44 (0)20 7383 6668 E: [email protected] Twitter: @ARD_BMJ ISSN: 0003-4967 (print) ISSN: 1468-2060 (online) Impact Factor: 9.270 396 A Ogdie, Y D Yu, K Haynes, T J Love, S Maliha, Y Jiang, A B Troxel, S Hennessy, S E Kimmel, D J Margolis, H Choi, N N Mehta, J M Gelfand Tore K Kvien Francis Berenbaum Hans Bijlsma David Pisetsky Dimitrios Boumpas Gerd Burmester Mary Crow Iain McInnes Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study OPEN ACCESS This article has been made freely available online under the BMJ Journals Open Access scheme. See http://ard.bmj.com/site/about/guidelines.xhtml#open This journal is a member of and subscribes to the principles of the Committee on Publication Ethics http://publicationethics.org/ Contents 430 OPEN ACCESS The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor Volume 74 Issue 2 | ARD February 2015 Letters 470 L R Harrold, G W Reed, J M Kremer, J R Curtis, D H Solomon, M C Hochberg, J D Greenberg 437 Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years T van den Broek, E Hoppenreijs, J Meerding, R Scholman, H G Otten, J F Swart, A Martini, B Prakken, W de Jager 472 S Tan, J Yao, J A Flynn, L Yao, M M Ward Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis 474 Z Jenei-Lanzl, S Capellino, F Kees, M Fleck, T Lowin, R H Straub 452 Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming K V Rupanagudi, O P Kulkarni, J Lichtnekert, M N Darisipudi, S R Mulay, B Schott, S Gruner, W Haap, G Hartmann, H-J Anders TNF␣ regulates cortisol metabolism in vivo in patients with inflammatory arthritis D E Nanus, A D Filer, B Hughes, B A Fisher, P C Taylor, P M Stewart, C D Buckley, I McInnes, M S Cooper, K Raza Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs E H Vogelzang, M F Pouw, M Nurmohamed, E L Kneepkens, T Rispens, G J Wolbink, C L M Krieckaert 475 The EULAR Outcome Measures Library: an evolutional database of validated patient-reported instruments I Castrejón, L Gossec, L Carmona Correction 476 464 The effect of mindfulness-based stress reduction on disease activity in people with rheumatoid arthritis: a randomised controlled trial F A Fogarty, R J Booth, G D Gamble, N Dalbeth, N S Consedine Basic and translational research 444 Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis Correction Electronic page e11 Thank you to our reviewers 2014